Protein and Energy Nutrition among Adult Patients Treated with Chronic Peritoneal Dialysis

Advances in Renal Replacement Therapy

Volumn 10, Issue 3, 2003, Pages 194-212

  Mehrotra, Rajnish ^a   Kopple, Joel D ^b  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b NONE

Author keywords

Anorexia; Hormones; Intraperitoneal amino acids; Metabolic acidosis; Nutrition; Peritoneal dialysis; Protein energy malnutrition

Indexed keywords

AMINO ACID; ANABOLIC AGENT; ANDROGEN; ANTIINFLAMMATORY AGENT; APPETITE STIMULANT; BICARBONATE; CARNITINE; CISAPRIDE; ERYTHROMYCIN; HUMAN GROWTH HORMONE; METOCLOPRAMIDE; NANDROLONE DECANOATE; ONDANSETRON; PROKINETIC AGENT; SOMATOMEDIN C;

ANOREXIA; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; CONFERENCE PAPER; DIET SUPPLEMENTATION; DIETARY INTAKE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG INDICATION; ENDOCRINE DISEASE; GENERAL CONDITION IMPROVEMENT; HUMAN; HYPERLEPTINEMIA; HYPOALBUMINEMIA; INFLAMMATION; LONG TERM CARE; MALNUTRITION; METABOLIC ACIDOSIS; METABOLIC DISORDER; MORBIDITY; MORTALITY; PATIENT COUNSELING; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PROTEIN CALORIE MALNUTRITION; QUALITY OF LIFE; RISK FACTOR; SIDE EFFECT; SODIUM RETENTION; TREATMENT INDICATION; UREMIA; WATER RETENTION;

EID: 0346154745     PISSN: 10734449     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.arrt.2003.08.005     Document Type: Conference Paper

References (194)

1. Canada-USA Peritoneal Dialysis Study Group: Adequacy of dialysis and nutrition in continuous peritoneal dialysis: Association with clinical outcomes. J Am Soc Nephrol 7:198-207, 1996
2. Sreedhara R, Avram MM, Blanco M, et al: Prealbumin is the best nutritional predictor of survival in hemodialysis and peritoneal dialysis. Am J Kidney Dis 28:937-942, 1996
3. Park JS, Jung HH, Yang WS, et al: Protein intake and the nutritional status in patients with pre-dialysis chronic renal failure on unrestricted diet. Korean J Intern Med 12:115-121, 1997
4. Chung SH, Lindholm B, Lee HB: Influence of initial nutritional status on continuous ambulatory peritoneal dialysis patient survival. Perit Dial Int 20:19-26, 2000
5. Tan SH, Lee E, Tay ME, et al: Protein nutritional status of adult patients starting chronic ambulatory peritoneal dialysis. Adv Perit Dial 16:291-296, 2000
6. Sutton D, Talbot ST, Stevens JM: Is there a relationship between diet and nutrition status in continuous ambulatory peritoneal dialysis patients? Perit Dial Int 21:S168-173, 2001
7. Pollock CA, Allen BJ, Warden RA, et al: Total-body nitrogen by neutron activation in maintenance dialysis. Am J Kidney Dis 16:38-45, 1990
8. Johansson AC, Samuelsson O, Haraldsson B, et al: Body composition in patients treated with peritoneal dialysis. Nephrol Dial Transplant 13:1511-1517, 1998
9. Lindholm B, Alvestrand A, Furst P, et al: Plasma and muscle free amino acids during continuous ambulatory peritoneal dialysis. Kidney Int 35:1219-1226, 1989
10. Palop L, Vega N, Rodriguez T, et al: Nutritional status of CAPD patients at three years. Nephrol Dial Transplant 16:S195-S202, 1996 (suppl)
11. Guarnieri G, Toigo G, Situlin R, et al: Muscle biopsy studies in chronically uremic patients: evidence for malnutrition. Kidney Int Suppl 16:S187-193, 1983
12. Jones CH, Newstead CG, Will EJ, et al: Assessment of nutritional status in CAPD patients: Serum albumin is not a useful measure. Nephrol Dial Transplant 12:1406-1413, 1997
13. Jacob V, Marchant PR, Wild G, et al: Nutritional profile of continuous ambulatory peritoneal dialysis patients. Nephron 71:16-22, 1995
14. Young GA, Kopple JD, Lindholm B, et al: Nutritional assessment of continuous ambulatory peritoneal dialysis patients. Am J Kidney Dis 17:462-471, 1991
15. Cianciaruso B, Brunori G, Kopple JD, et al: Cross-sectional comparison of malnutrition in continuous ambulatory peritoneal dialysis and hemodialysis patients: Am J Kidney Dis 26:475-486, 1995
16. Heimburger O, Qureshi AR, Blaner WS, et al: Hand-grip muscle strength, lean body mass, and plasma proteins as markers of nutritional status in patients with chronic renal failure close to start of dialysis therapy. Am J Kidney Dis 36:1213-1225, 2000
17. Chung SH, Na MH, Lee SH, et al: Nutritional status of Korean peritoneal dialysis patients. Perit Dial Int 19:S517-522, 1999 (suppl)
18. Lo WK, Tong KL, Li CS, et al: Relationship between adequacy of dialysis and nutritional status, and their impact on patient survival on CAPD in Hong Kong. Perit Dial Int 21:441-447, 2001
19. Iseki K, Uehara H, Nishime K, et al: Impact of the initial levels of laboratory variables on survival in chronic dialysis patients. Am J Kidney Dis 28:541-548, 1996
20. McCusker FX, Teehan BP, Thorpe KE, et al: How much peritoneal dialysis is necessary for maintaining a good nutritional status? Kidney Int 56:S56-S61, 1996 (suppl)
21. Teehan BP, Schleifer CR, Brown JM, et al: Urea kinetic analysis and clinical outcome in CAPD: a five-year longitudinal study. Adv Perit Dial 6:181-185, 1990
22. Blake PG, Flowerdew G, Blake R, et al: Serum albumin in patients on continuous ambulatory peritoneal dialysis-Predictors and correlations with outcomes. J Am Soc Nephrol 3:1501-1510, 1993
23. Rocco MV, Jordan JR, Burkart JM: The efficacy number as a predictor of morbidity and mortality in peritoneal dialysis patients. J Am Soc Nephrol 4:1184-1191, 1993
24. Avram MM, Mittman N, Bonomini L, et al: Markers for survival in dialysis: A seven-year prospective study. Am J Kidney Dis 26:209-219, 1995
25. Davies SJ, Russell L, Bryan J, et al: Comorbidity, urea kinetics, and appetite in continuous ambulatory peritoneal dialysis patients: Their interrelationship and prediction of survival. Am J Kidney Dis 26:353-361, 1995
26. Harty J, Conway L, Keegan M, et al: Energy metabolism during CAPD: A controlled study. Adv Perit Dial 11:229-233, 1995
27. Bergstrom J, Furst P, Alvestrand A, et al: Protein and energy intake, nitrogen balance and nitrogen losses in patients treated with continuous ambulatory peritoneal dialysis. Kidney Int 44:1048-1057, 1993
28. National Kidney Foundation I, Kidney-Dialysis Outcome Quality Initiative: Clinical practice guidelines for nutrition in chronic renal failure. Am J Kidney Dis 35:S1-S140, 2000
29. Giordano C, De Santo G, Pluvio M, et al: Protein requirements of patients on CAPD: A study of nitrogen balance. Int J Artif Org 3:11-14, 1980
30. Blumenkrantz MJ, Kopple JD, Moran JK, et al: Metabolic balance studies and dietary protein requirements in patients undergoing continuous ambulatory peritoneal dialysis. Kidney Int 21:849-861, 1982
31. Nolph KD, Moore HL, Prowant B, et al: Cross sectional assessment of weekly urea and creatinine clearances and indices of nutrition in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 13:178-183, 1993
32. Fernstrom A, Hylander B, Rossner S: Energy intake in patients on continuous ambulatory peritoneal dialysis and haemodialysis. J Intern Med 240:211-218, 1996
33. Caravaca F, Arrobas M, Dominguez C: Influence of residual renal function on dietary protein and caloric intake in patients on incremental peritoneal dialysis. Perit Dial Int 19:350-356, 1999
34. Park YK, Kim JH, Kim KJ, et al: A cross-sectional study comparing the nutritional status of peritoneal dialysis and hemodialysis patients in Korea. J Ren Nutr 9:149-156, 1999
35. Saltissi D, Morgan C, Knight B, et al: Effect of lipid-lowering dietary recommendations on the nutritional intake and lipid profiles of chronic peritoneal dialysis and hemodialysis patients. Am J Kidney Dis 37:1209-1215, 2001
36. Wang AY, Sanderson J, Sea MM, et al: Important factors other than dialysis adequacy associated with inadequate dietary protein and energy intakes in patients receiving maintenance peritoneal dialysis. Am J Clin Nutr 77:834-841, 2003
37. Briganti M, Emiliani G, Montanari A, et al: Longitudinal assessment of body composition in CAPD patients using bioelectric impedance analysis. A comparison with hemodialysis patients. ASAIO J 41:M725-727, 1995
38. Young GA, Young JB, Young SM, et al: Nutrition and delayed hypersensitivity during continuous ambulatory peritoneal dialysis in relation to peritonitis. Nephron 43:177-186, 1986
39. Edefonti A, Picca M, Damiani B, et al: Dietary prescription based on estimated nitrogen balance during peritoneal dialysis. Pediatr Nephrol 13:253-258, 1999
40. Pollock CA, Ibels LS, Allen BJ, et al: Total body nitrogen as a prognostic marker in maintenance dialysis. J Am Soc Nephrol 6:82-88, 1995
41. Pollock CA, Ibels LS, Caterson RJ, et al: Continuous ambulatory peritoneal dialysis. Eight years of experience at a single center. Medicine (Baltimore) 68:293-308, 1989
42. Aguilera A, Codoceo R, Bajo MA, et al: Helicobacter pylori infection: A new cause of anorexia in peritoneal dialysis patients. Perit Dial Int 21: S152-156, 2001
43. Davies SJ, Phillips L, Griffiths AM, et al: Analysis of the effects of increasing delivered dialysis treatment to malnourished peritoneal dialysis patients. Kidney Int 57:1743-1754, 2000
44. Fung L, Pollock CA, Caterson RJ, et al: Dialysis adequacy and nutrition determine prognosis in continuous ambulatory peritoneal dialysis patients. J Am Soc Nephrol 7:737-744, 1996
45. Lindsay RM, Spanner E: A hypothesis: The protein catabolic rate is dependent upon the type and amount of treatment in dialyzed uremic patients. Am J Kidney Dis 13:382-389, 1989
46. Lysaght MJ, Pollock CA, Hallet MD, et al: The relevance of urea kinetic modeling to CAPD. ASAIO Trans 35:784-790, 1989
47. Bergstrom J, Alvestrand A, Lindholm B, et al: Relationship between Kt/V and protein catabolic rate (PCR) is different in continuous peritoneal dialysis and hemodialysis patients. J Am Soc Nephrol 2:358, 1991
48. Goodship TH, Pablick-Deetjen J, Ward MK, et al: Adequacy of dialysis and nutritional status in CAPD. Nephrol Dial Transplant 8:1366-1371, 1993
49. Tzamaloukas AH, Servilla KS, Murata GH, et al: Nutrition indices in obese continuous peritoneal dialysis patients with inadequate and adequate urea clearance. Perit Dial Int 22:506-512, 2002
50. Harty J, Boulton H, Faragher B, et al: The influence of small solute clearance on dietary protein intake in continuous ambulatory peritoneal dialysis patients: A methodologic analysis based on cross-sectional and prospective studies. Am J Kidney Dis 28:553-560, 1996
51. Uehlinger DE: Another look at the relationship between protein intake and dialysis dose. J Am Soc Nephrol 7:166-168, 1996
52. Wang AY, Sea MM, Ip R, et al: Independent effects of residual renal function and dialysis adequacy on actual dietary protein, calorie, and other nutrient intake in patients on continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 12:2450-2457, 2001
53. Mehrotra R, Saran R, Moore HL, et al: Toward targets for initiation of chronic dialysis. Perit Dial Int 17:497-508, 1997
54. Davies SJ, Russell L, Bryan J, et al: Impact of peritoneal absorption of glucose on appetite, protein catabolism and survival in CAPD patients. Clin Nephrol 45:194-198, 1996
55. Anderstam B, Mamoun AH, Sodersten P, et al: Middle-sized molecule fractions isolated from uremic ultrafiltrate and normal urine inhibit ingestive behavior in the rat. J Am Soc Nephrol 7:2453-2460, 1996
56. Aguilera A, Codoceo R, Selgas R, et al: Anorexigen (TNF-alpha, cholecystokinin) and orexigen (neuropeptide Y) plasma levels in peritoneal dialysis (PD) patients: Their relationship with nutritional parameters. Nephrol Dial Transplant 13:1476-1483, 1998
57. López-Menchero R, Miguel A, García-Ramón R, et al: Importance of residual renal function in continuous ambulatory peritoneal dialysis: Its influence on different parameters of renal replacement treatment. Nephron 83:219-225, 1999
58. Szeto CC, Lai KN, Wong TYH, et al: Independent effects of residual renal function and dialysis adequacy on nutritional status and patient outcome in continuous ambulatory peritoneal dialysis. Am J Kidney Dis 34:1056-1064, 1999
59. Pollock CA, Ibels LS, Zhu FY, et al: Protein intake in renal disease. J Am Soc Nephrol 8:777-783, 1997
60. Ginsberg N, Fishbane D, Lynn R: The effect of improved dialytic efficiencies on measures of appetite in peritoneal dialysis patients. J Ren Nutr 6:217-221, 1996
61. Malhotra D, Tzamaloukas AH, Murata GH, et al: Serum albumin in continuous ambulatory peritoneal dialysis: Its predictors and relationship to urea clearance. Kidney Int 50:243-249, 1996
62. Mak S-K, Wong P-N, Lo K-Y, et al: Randomized prospective study of the effect of increased dialytic dose on nutritional and clinical outcome in continuous ambulatory peritoneal dialysis patients. Am J Kidney Dis 36:105-114, 2000
63. Brown-Cartwright D, Smith HJ, Feldman M: Gastric emptying of an indigestible solid in patients with end-stage renal disease on continuous ambulatory peritoneal dialysis. Gastroenterology 95:49-51, 1988
64. Bird NJ, Streather CP, O'Doherty MJ, et al: Gastric emptying in patients with chronic renal failure on continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 9:287-290, 1994
65. Lee SW, Song JH, Kim GA, et al: Effect of dialysis modalities on gastric myoelectrical activity in end-stage renal disease patients. Am J Kidney Dis 36:566-573, 2000
66. Schoonjans R, Van Vlem B, Vandamme W, et al: Gastric emptying of solids in cirrhotic and peritoneal dialysis patients: Influence of peritoneal volume load. Eur J Gastroenterol Hepatol 14:395-398, 2002
67. Van V, Schoonjans RS, Struijk DG, et al: Influence of dialysate on gastric emptying time in peritoneal dialysis patients. Perit Dial Int 22:32-38, 2002
68. Kim DJ, Kang WH, Kim HY, et al: The effect of dialysate dwell on gastric emptying time in patients on continuous ambulatory peritoneal dialysis. Perit Dial Int 19:S176-178, 1999
69. Campfield LA, Smith FJ, Guisez Y, et al: Recombinant mouse OB protein: Evidence for a peripheral signal linking adiposity and central neural networks. Science 269:546-549, 1995
70. Halaas JL, Gajiwala KS, Maffei M, et al: Weight-reducing effects of the plasma protein encoded by the obese gene. Science 269:543-546, 1995
71. Pelleymounter MA, Cullen MJ, Baker MB, et al: Effects of the obese gene product on body weight regulation in ob/ob mice. Science 269:540-543, 1995
72. Heimburger O, Lonnqvist F, Danielsson A, et al: Serum immunoreactive leptin concentration and its relation to the body fat content in chronic renal failure. J Am Soc Nephrol 8:1423-1430, 1997
73. Howard JK, Lord GM, Clutterbuck EJ, et al: Plasma immunoreactive leptin concentration in end-stage renal disease. Clin Sci (Lond) 93:119-126, 1997
74. Young GA, Woodrow G, Kendall S, et al: Increased plasma leptin/fat ratio in patients with chronic renal failure: A cause of malnutrition? Nephrol Dial Transplant 12:2318-2323, 1997
75. Dagogo-Jack S, Ovalle F, Landt M, et al: Hyperleptinemia in patients with end-stage renal disease undergoing continuous ambulatory peritoneal dialysis. Perit Dial Int 18:34-40, 1998
76. Johansen KL, Mulligan K, Tai V, et al: Leptin, body composition, and indices of malnutrition in patients on dialysis. J Am Soc Nephrol 9:1080-1084, 1998
77. Fontan MP, Rodriguez-Carmona A, Cordido F, et al: Hyperleptinemia in uremic patients undergoing conservative management, peritoneal dialysis, and hemodialysis: A comparative analysis. Am J Kidney Dis 34:824-831, 1999
78. Stenvinkel P, Lindholm B, Lonnqvist F, et al: Increases in serum leptin levels during peritoneal dialysis are associated with inflammation and a decrease in lean body mass. J Am Soc Nephrol 11:1303-1309, 2000
79. Parry RG, Johnson DW, Carey DG, et al: Serum leptin correlates with fat mass but not dietary energy intake in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 18:569-575, 1998
80. Nordfors L, Lönnqvist F, Heimbürger O, et al: Low leptin gene expression and hyperleptinemia in chronic renal failure. Kidney Int 54: 1267-1275, 1998
81. Stenvinkel P, Heimbürger O, Lönnqvist F: Serum leptin concentrations correlate to plasma insulin concentrations independent of body fat content in chronic renal failure. Nephrol Dial Transplantation 12:1321-1325, 1997
82. Fouque D, Juillard L, Lasne Y, et al: Acute leptin regulation in end-stage renal failure: The role of growth hormone and 1GF-1. Kidney Int 54:932-937, 1998
83. Kolaczvnski IW, Nyce MR, Considine RV, et al: Acute and chronic effects of insulin on leptin production in humans: Studies in vivo and in vitro. Diabetes 45:699-701, 1996
84. Malmstrom R, Taskinen MR, Karonen SL, et al: Insulin increases plasma leptin concentrations in normal subjects and patients with NIDDM. Diabetologia 39:993-996, 1996
85. Kagan A, Haran N, Leschinsky L, et al: Leptin in CAPD patients: Serum concentrations and peritoneal loss. Nephrol Dial Transplant 14:400-405, 1999
86. de Precigout V, Chauveau P, Delclaux C, et al: No change of hyperleptinemia despite a decrease in insulin concentration in patients with chronic renal failure on a supplemented very low protein diet. Am J Kidney Dis 36:1201-1206, 2000
87. Kokot F, Adamczak M, Wiecek A: Plasma leptin concentration in kidney transplant patients during the early post-transplant period. Nephrol Dial Transplant 13:2276-2280, 1998
88. Landt M, Brennan DC, Parvin CA, et al: Hyperleptinaemia of end-stage renal disease is corrected by renal transplantation. Nephrol Dial Transplant 13:2271-2275, 1998
89. Arkouche W, Juillard L, Delawari E, et al: Peritoneal clearance of leptin in continuous ambulatory peritoneal dialysis. Am J Kidney Dis 34:839-844, 1999
90. Heimbürger O, Wang T, Lönnqvist F, et al: Peritoneal clearance of leptin in CAPD patients: Impact of local insulin administration. Nephrol Dial Transplant 14:723-727, 1999
91. Tsujimoto Y, Shoji T, Tabata T, et al: Leptin in peritoneal dialysate from continuous ambulatory peritoneal dialysis patients. Am J Kidney Dis 34:832-838, 1999
92. Landt M, Parvin CA, Dagogo-Jack S, et al: Leptin elimination in hyperleptinaemic peritoneal dialysis patients. Nephrol Dial Transplant 14:732-737, 1999
93. Don BR, Rosales LM, Levine NW, et al: Leptin is a negative acute phase protein in chronic hemodialysis patients. Kidney Int 59:1114-1120, 2001
94. Hylander B, Barkeling B, Rossner S: Eating behavior in continuous ambulatory peritoneal dialysis and hemodialysis patients. Am J Kidney Dis 20:592-597, 1992
95. Hylander B, Barkeling B, Rossner S: Changes in patients' eating behavior: In the uremic state, on continuous ambulatory peritoneal dialysis treatment, and after transplantation. Am J Kidney Dis 29:691-698, 1997
96. Balaskas EV, Rodela H, Oreopoulos DG: Effects of intraperitoneal infusion of dextrose and amino acids on the appetite of rabbits. Perit Dial Int 13:S490-498, 1993
97. Mamoun AH, Anderstam B, Sodersten P, et al: Influence of peritoneal dialysis solutions with glucose and amino acids on ingestive behavior in rats. Kidney Int 49:1276-1282, 1996
98. United States Renal Data System: US Department of Public Health and Human Services, Public Health Service. Bethesda, MD, National Institutes of Health, 2002
99. United States Renal Data System: US Department of Public Health and Human Services, Public Health Service. Bethesda, MD, National Institutes of Health, 1998
100. Davies SJ, Russell L, Bryan J, et al: Comorbidity, urea kinetics, and appetite in continuous ambulatory peritoneal dialysis patients: Their interrelationship and prediction of survival. Am J Kidney Dis 26:353-361, 1995
101. Caravaca F, Arrobas M, Pizarro JL, et al: Uraemic symptoms, nutritional status and renal function in pre-dialysis end-stage renal failure patients. Nephrol Dial Transplant 16:776-782, 2001
102. Tzamaloukas AH, Oreopoulos DG, Murata GH, et al: The relation between nutrition indices and age in patients on continuous ambulatory peritoneal dialysis receiving similar small solute clearances. Int Urol Nephrol 32:449-458, 2001
103. Krieg RJ Jr, Santos F, Chan JC: Growth hormone, insulin-like growth factor and the kidney. Kidney Int 48:321-336, 1995
104. Ding H, Gao XL, Hirschberg R, et al: Impaired actions of insulin-like growth factor 1 on protein Synthesis and degradation in skeletal muscle of rats with chronic renal failure. Evidence for a postreceptor defect. J Clin Invest 97:1064-1075, 1996
105. Castellino P, Solini A, Luzi L, et al: Glucose and amino acid metabolism in chronic renal failure: Effect of insulin and amino acids. Am J Physiol 262: F168-176, 1992
106. Chan W, Valerie KC, Chan JC: Expression of insulin-like growth factor-1 in uremic rats: Growth hormone resistance and nutritional intake. Kidney Int 43:790-795, 1993
107. Tönshoff B, Edén S, Weiser E, et al: Reduced hepatic growth hormone (GH) receptor gene expression and increased plasma GH binding protein in experimental uremia. Kidney Int 45:1085-1092, 1994
108. DeFronzo RATJ, Rowe JW, Andres R: Glucose intolerance in uremia: quantification of pancreatic beta cell sensitivity to glucose and tissue sensitivity to insulin. J Clin Inves 62:425-435, 1978
109. Fouque D, Peng SC, Kopple JD: Impaired metabolic response to recombinant insulin-like growth factor-1 in dialysis patients. Kidney Int 47:876-883, 1995
110. Sherwin RS, Bastl C, Finkelstein FO, et al: Influence of uremia and hemodialysis on the turnover and metabolic effects of glucagon. J Clin Invest 57:722-731, 1976
111. Moxley MA, Bell NH, Wagle SR, et al: Parathyroid hormone stimulation of glucose and urea production in isolated liver cells. Am J Physiol 227:1058-1061, 1974
112. Yonemura K, Fujimoto T, Fujigaki Y, et al: Vitamin D deficiency is implicated in reduced serum albumin concentrations in patients with end-stage renal disease. Am J Kidney Dis 36:337-344, 2000
113. Reaich D, Channon SM, Scrimgeour CM, et al: Ammonium chloride-induced acidosis increases protein breakdown and amino acid oxidation in humans. Am J Physiol 263:E735-739, 1992
114. Ballmer PE, McNurlan MA, Hulter HN, et al: Chronic metabolic acidosis decreases albumin synthesis and induces negative nitrogen balance in humans. J Clin Invest 95:39-45, 1995
115. Mitch WE, Medina R, Grieber S, et al: Metabolic acidosis stimulates muscle protein degradation by activating the adenosine triphosphate-dependent pathway involving ubiquitin and proteasomes. J Clin Invest 93:2127-2133, 1994
116. Bailey JL, Wang X, England BK, et al: The acidosis of chronic renal failure activates muscle proteolysis in rats by augmenting transcription of genes encoding proteins of the ATP-dependent ubiquitin-proteasome pathway. J Clin Invest 97:1447-1453, 1996
117. Graham KA, Reaich D, Channon SM, et al: Correction of acidosis in CAPD decreases whole body protein degradation. Kidney Int 49:1396-1400, 1996
118. Pickering WP, Price SR, Bircher G, et al: Nutrition in CAPD: Serum bicarbonate and the ubiquitin-proteasome system in muscle. Kidney Int 61:1286-1292, 2002
119. Katirtzoglou A, Oreopoulos DG, Husdan H, et al: Reappraisal of protein losses in patients undergoing continuous ambulatory peritoneal dialysis. Nephron 26:230-233, 1980
120. Blumenkrantz MJ, Gahl GM, Kopple JD, et al: Protein losses during peritoneal dialysis. Kidney Int 19:593-602, 1981
121. Kopple JD, Blumenkrantz MJ, Jones MR, et al: Plasma amino acid levels and amino acid losses during continuous ambulatory peritoneal dialysis. Am J Clin Nutr 36:395-402, 1982
122. Kumano K, Kawaguchi Y: Multicenter cross-sectional study for dialysis dose and physician's subjective judgment in Japanese peritoneal dialysis patients. Group for the Water and Electrocyte Balance Study in CAPD. Am J Kidney Dis 35:515-525, 2000
123. Kaysen GA, Schoenfeld PY: Albumin homeostasis in patients undergoing continuous ambulatory peritoneal dialysis. Kidney Int 25:107-114, 1984
124. Heaf J: CAPD adequacy and dialysis morbidity: Detrimental effect of a high peritoneal equilibration rate. Ren Fail 17:575-587, 1995
125. Churchill DN, Thorpe KE, Nolph KD, et al: Increased peritoneal membrane transport is associated with decreased patient and technique survival for continuous peritoneal dialysis patients. The Canada-USA (CANUSA) Peritoneal Dialysis Study Group. J Am Soc Nephrol 9:1285-1292, 1998
126. Davies SJ, Phillips L, Griffiths AM, et al: What really happens to people on long-term peritoneal dialysis? Kidney Int 54:2207-2217, 1998
127. Wang T, Heimburger O, Waniewski J, et al: Increased peritoneal permeability is associated with decreased fluid and small-solute removal and higher mortality in CAPD patients. Nephrol Dial Transplant 13:1242-1249, 1998
128. Stenvinkel P, Chung SH, Heimburger O, et al: Malnutrition, inflammation, and atherosclerosis in peritoneal dialysis patients. Perit Dial Int 21:S157-162, 2001
129. Nolph KD, Moore HL, Prowant B, et al: Continuous ambulatory peritoneal dialysis with a high flux membrane. ASAIO J 39:904-909, 1993
130. Harty JC, Boulton H, Venning MC, et al: Is peritoneal permeability an adverse risk factor for malnutrition in CAPD patients? Miner Electrolyte Metab 22:97-101, 1996
131. Cueto-Manzano AM, Espinosa A, Hernandez A, et al: Peritoneal transport kinetics correlate with serum albumin but not with the overall nutritional status in CAPD patients. Am J Kidney Dis 30:229-236, 1997
132. Kang DH, Yoon KI, Choi KB, et al: Relationship of peritoneal membrane transport characteristics to the nutritional status in CAPD patients. Nephrol Dial Transplant 14:1715-1722, 1999
133. Szeto CC, Law MC, Wong TY, et al: Peritoneal transport status correlates with morbidity but not longitudinal change of nutritional status of continuous ambulatory peritoneal dialysis patients: A 2-year prospective study. Am J Kidney Dis 37:329-336, 2001
134. Ates K, Oztemel A, Nergizoglu G, et al: Peritoneal protein losses do not have a significant impact on nutritional status in CAPD patients. Perit Dial Int 21:519-522, 2001
135. Bannister DK, Acchiardo SR, Moore LW, et al: Nutritional effects of peritonitis in continuous ambulatory peritoneal dialysis (CAPD) patients. J Am Diet Assoc 87:53-56, 1987
136. Heimburger O, Stenvinkel P, Berglund L, et al: Increased plasma lipoprotein(a) in continuous ambulatory peritoneal dialysis is related to peritoneal transport of proteins and glucose. Nephron 72:135-144, 1996
137. Lindsay RM, Spanner E, Heidenheim RP, et al: Which comes first, Kt/V or PCR-chicken or egg? Kidney Int Suppl 38:S32-36, 1992
138. Williams P, Jones J, Marriott J: Do increases in dialysis dose in CAPD patients lead to nutritional improvements? Nephrol Dial Transplant 9:1841-1842, 1994
139. Eisenberg B, Murata GH, Tzamaloukas AH, et al: Gastroparesis in diabetics on chronic dialysis: clinical and laboratory associations and predictive features. Nephron 70:296-300, 1995
140. Ross EA, Koo LC: Improved nutrition after the detection and treatment of occult gastroparesis in nondiabetic dialysis patients. Am J Kidney Dis 31:62-66, 1998
141. Silang R, Regalado M, Cheng TH, et al: Prokinetic agents increase plasma albumin in hypoalbuminemic chronic dialysis patients with delayed gastric emptying. Am J Kidney Dis 37:287-293, 2001
142. Seibert DG, Moss AH, Holley JL, et al: Intraperitoneal metoclopramide improves symptoms of gastroparesis in a CAPD patient. Perit Dial Int 9:223-224, 1989
143. Wadhwa NK, Atkins H, Cabralda T: Intraperitoneal erythromycin for gastroparesis. Ann Intern Med 114:912, 1991
144. Gallar P, Vigil A, Oliet A, et al: Intraperitoneal erythromycin for diabetic gastroparesis in CAPD. Perit Dial Int 12:265-266, 1992
145. Gallar P, Oliet A, Vigil A, et al: Gastroparesis: An important cause of hospitalization in continuous ambulatory peritoneal dialysis patients and the role of erythromycin. Perit Dial Int 13:S183-186, 1993
146. de Graaf-Strukowska L, van Hees CA, Ferwerda J, et al: Two non-diabetic patients with delayed gastric emptying during CAPD effectively treated with erythromycin. Nephrol Dial Transplant 10:2349-2350, 1995
147. Amin K, Bastani B: Intraperitoneal ondansetron hydrochloride for intractable nausea and vomiting due to diabetic gastroparesis in a patient on peritoneal dialysis. Perit Dial Int 22:539-540, 2002
148. Lazarovits AI, Page D: Intraperitoneal cisa-pride for the treatment of diabetics with gastroparesis and end-stage renal disease. Nephron 56:107-109, 1990
149. Schoonjans R, Van VB, Vandamme W, et al: Dyspepsia and gastroparesis in chronic renal failure: The role of Helicobacter pylori: Clin Nephrol 57:201-207, 2002
150. Lien YH, Ruffenach SJ: Low dose megestrol increases serum albumin in malnourished dialysis patients. Int J Artif Organs 19:147-150, 1996
151. Boudville N, Rangan A, Moody H: Oral nutritional supplementation increases caloric and protein intake in peritoneal dialysis patients. Am J Kidney Dis 41:658-663, 2003
152. Elias RA, McArdle AH, Gagnon RF: The effectiveness of protein supplementation on the nutritional management of patients on CAPD. Adv Perit Dial 5:177-180, 1989
153. Shimomura A, Tahara D, Azekura H: Nutritional improvement in elderly CAPD patients with additional high protein foods. Adv Perit Dial 9:80-86, 1993
154. Heaf JG, Honore K, Valeur D, et al: The effect of oral protein supplements on the nutritional status of malnourished CAPD patients. Perit Dial Int 19:78-81, 1999
155. West NR: Gastrostomy feeding a patient receiving PD. Edtna Erca J 23:19-21, 1997
156. Fein PA, Madane SJ, Jorden A, et al: Outcome of percutaneous endoscopic gastrostomy feeding in patients on peritoneal dialysis. Adv Perit Dial 17:148-152, 2001
157. Ramage IJ, Geary DF, Harvey E, et al: Efficacy of gastrostomy feeding in infants and older children receiving chronic peritoneal dialysis. Perit Dial Int 19:231-236, 1999
158. Goel S, Ribby KJ, Kathuria P, et al: Temporary stoppage of peritoneal dialysis when laparoscopic procedures are performed on patients undergoing CAPD/CCPD: A change in policy. Adv Perit Dial 14:80-82, 1998
159. Jones MR, Gehr TW, Burkart JM, et al: Replacement of amino acid and protein losses with 1.1% amino acid peritoneal dialysis solution. Perit Dial Int 18:210-216, 1998
160. Gjessing J: Addition of aminoacids to peritoneal-dialysis fluid. Lancet 2:812, 1968
161. Jackson MA, Talbot S, Thomas DW, et al: Prevention of amino acid losses during peritoneal dialysis. Postgrad Med J 55:533-536, 1979
162. Oreopoulos DG, Marliss E, Anderson GH, et al: Nutritional aspects of CAPD and the potential use of amino acid containing dialysis solutions. Perit Dial Bull 3:S10-S15, 1982
163. Kopple JD, Bernard D, Messana J, et al: Treatment of malnourished CAPD patients with an amino acid based dialysate. Kidney Int 47:1148-1157, 1995
164. Faller B, Aparicio M, Faict D, et al: Clinical evaluation of an optimized 1.1% amino-acid solution for peritoneal dialysis. Nephrol Dial Transplant 10:1432-1437, 1995
165. Chertow GM, Lazarus JM, Lyden ME, et al: Laboratory surrogates of nutritional status after administration of intraperitoneal amino aid-based solutions in ambulatory peritoneal dialysis patients. J Ren Nutr 5:116-123, 1995
166. Misra M, Reaveley DA, Ashworth J, et al: Six-month prospective cross-over study to determine the effects of 1.1% amino acid dialysate on lipid metabolism in patients on continuous ambulatory peritoneal dialysis. Perit Dial Int 17:279-286, 1997
167. Jones M, Hagen T, Algrim Boyle C, et al: Treatment of malnutrition with 1.1% amino acid peritoneal dialysis solution: Results of a multicenter study. Am J Kidney Dis 32:761-769, 1998
168. Jones CH, Smith M, Henderson MJ, et al: Fasting plasma amino acids are not normalized by 12-month amino acid-based dialysate in CAPD patients. Perit Dial Int 19:174-177, 1999
169. Maurer O, Saxenhofer H, Jaeger P, et al: Six-month overnight administration of intraperitoneal amino acids does not improve lean mass. Clin Nephrol 45:303-309, 1996
170. Grzegorzewska AE, Mariak I, Dobrowolska-Zachwieja A, et al: Effects of amino acid dialysis solution on the nutrition of continuous ambulatory peritoneal dialysis patients. Perit Dial Int 19:462-470, 1999
171. Gonzalez AO, Melon CP, Esteban J, et al: Intraperitoneal amino acids in CAPD: An 18 month experience. Perit Dial Int 19:494-496, 1999
172. Taylor GS, Patel V, Spencer S, et al: Long term use of 1.1% amino acid dialysis solution in hypoalbuminemic continuous ambulatory peritoneal dialysis patients. Clin Nephrol 58:445-450, 2002
173. Li FK, Chan LYY, Woo JCY, et al: A 3-year, prospective, randomized, controlled study on amino acid dialysate in patients on CAPD. Am J Kidney Dis 42:173-183, 2003
174. Delarue J, Maingourd C, Objois M, et al: Effects of an amino acid dialysate on leucine metabolism in continuous ambulatory peritoneal dialysis patients. Kidney Int 56:1934-1943, 1999
175. Brulez HF, van Guldener C, Donker AJ, et al: The impact of an amino acid-based peritoneal dialysis fluid on plasma total homocysteine levels, lipid profile and body fat mass. Nephrol Dial Transplant 14:154-159, 1999
176. Stein A, Bennett S, Feehally J, et al: Does low-calcium dialysate improve the nutritional status of CAPD patients? Perit Dial Int 13:69, 1993
177. Stein A, Moorhouse J, Iles-Smith H, et al: Role of an improvement in acid-base status and nutrition in CAPD patients. Kidney Int 52:1089-1095, 1997
178. Szeto CC, Wong TY, Chow KM, et al: Oral sodium bicarbonate for the treatment of metabolic acidosis in peritoneal dialysis patients: A randomized, placebo-control trial. J Am Soc Nephrol 14:2119-2126, 2003
179. Gallieni M, Cozzolino M, Brancaccio D: Transient decrease of serum bicarbonate levels with Sevelamer hydrochloride as the phosphate binder. Kidney Int 57:1776-1777, 2000
180. Sadek T, Mazouz H, Bahloul H, et al: Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open-label, randomized study. Nephrol Dial Transplant 18:582-589, 2003
181. Marco MP, Muray S, Betriu A, et al: Treatment with sevelamer decreases bicarbonate levels in hemodialysis patients. Nephron 92:499-500, 2002
182. Ikizler TA, Wingard RL, Breyer JA, et al: Short-term effects of recombinant human growth hormone in CAPD patients. Kidney Int 46:1178-1183, 1994
183. Ikizler TA, Wingard RL, Flakoll PJ, et al: Effects of recombinant human growth hormone on plasma and dialysate amino acid profiles in CAPD patients. Kidney Int 50:229-234, 1996
184. Sanaka T, Sugino N: Improvement of malnutrition indices in adult patients with end stage renal disease by recombinant human growth hormone. Nippon Jinzo Gakkai Shi 33:1153-1159, 1991
185. Iglesias P, Diez JJ, Fernandez-Reyes MJ, et al: Recombinant human growth hormone therapy in malnourished dialysis patients: A randomized controlled study. Am J Kidney Dis 32:454-463, 1998
186. Iglesias P, Diez JJ, Fernandez-Reyes MJ, et al: Effects of short-term recombinant human growth hormone therapy on plasma leptin concentrations in dialysis patients. Nephrol Dial Transplant 17:260-264, 2002
187. Tayek JA, Brasel JA: Failure of anabolism in malnourished cancer patients receiving growth hormone: A clinical research center study. J Clin Endocrinol Metab 80:2082-2087, 1995
188. Jenkins RC, Ross RJ: Acquired growth hormone resistance in catabolic states. Baillieres Clin Endocrinol Metab 10:411-419, 1996
189. Fouque D, Peng SC, Shamir E, et al: Recombinant human insulin-like growth factor-1 induces an anabolic response in malnourished CAPD patients. Kidney Int 57:646-654, 2000
190. Dombros NV, Digenis GE, Soliman G, et al: Anabolic steroids in the treatment of malnourished CAPD patients: A retrospective study. Perit Dial Int 14:344-347, 1994
191. Navarro JF, Mora-Fernandez C, Rivero A, et al: Androgens for the treatment of anemia in peritoneal dialysis patients. Adv Perit Dial 14:232-235, 1998
192. Johansen KL, Mulligan K, Schambelan M: Anabolic effects of nandrolone decanoate in patients receiving dialysis: A randomized controlled trial. JAMA 281:1275-1281, 1999
193. Navarro JF, Mora C, Macia M, et al: Randomized prospective comparison between erythropoietin and androgens in CAPD patients. Kidney Int 61:1537-1544, 2002
194. Kopple JD, Qing DP: Effect of L-carnitine on nitrogen balance in CAPD subjects. J Am Soc Nephrol 10:264A, 1999 (abstr)